Aprindine: Difference between revisions

Jump to navigation Jump to search
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
No edit summary
 
Line 1: Line 1:
{{drugbox |
{{Drugbox
| IUPAC_name = ''N''<nowiki>'</nowiki>-(2,3-dihydro-1''H''-inden-2-yl)-''N'',''N''-diethyl-''N''<nowiki>'</nowiki>-<br>phenyl-propane-1,3-diamine
| verifiedrevid = 443395414
| IUPAC_name = {3-[2,3-dihydro-1''H''-inden-2-yl(phenyl)amino]propyl}diethylamine
| image = Aprindine_svg.png
| image = Aprindine_svg.png
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|aprindine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL        / P      / POM / CD -->
| legal_US = <!-- OTC                  / Rx-only  -->
| legal_status = 
| routes_of_administration = 
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number = 37640-71-4
| CAS_number = 37640-71-4
| ATC_prefix = C01
| ATC_prefix = C01
| ATC_suffix = BB04
| ATC_suffix = BB04
| PubChem = 2218
| PubChem = 2218
| DrugBank =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| C = 22 | H = 30 | N = 2  
| DrugBank = DB01429
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2132
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5Y48085P9Q
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02969
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1213033
 
<!--Chemical data-->
| C=22 | H=30 | N=2  
| molecular_weight = 322.487 g/mol
| molecular_weight = 322.487 g/mol
| bioavailability =  
| smiles = c1cccc3c1CC(N(c2ccccc2)CCCN(CC)CC)C3
| protein_bound =  
| InChI = 1/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3
| metabolism =  
| InChIKey = NZLBHDRPUJLHCE-UHFFFAOYAO
| elimination_half-life =  
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| excretion =
| StdInChI = 1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| pregnancy_US =  <!-- A / B            / C / D / X -->
| StdInChIKey = NZLBHDRPUJLHCE-UHFFFAOYSA-N
| pregnancy_category = 
| legal_AU =      <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK =      <!-- GSL        / P      / POM / CD -->
| legal_US =      <!-- OTC                  / Rx-only  -->
| legal_status =  
| routes_of_administration =  
}}
}}
__NOTOC__
__NOTOC__
{{SI}}
{{CMG}}
{{CMG}}


==Overview==
'''Aprindine''' is a Class 1b [[antiarrhythmic agent]].<ref name="pmid1660104">{{cite journal |author=Sato R, Hisatome I, Tanaka Y, ''et al.'' |title=Aprindine blocks the sodium current in guinea-pig ventricular myocytes |journal=Naunyn Schmiedebergs Arch. Pharmacol. |volume=344 |issue=3 |pages=331–6 |date=September 1991 |pmid=1660104 |doi= 10.1007/bf00183008|url=}}</ref>


In one study, it delayed [[atrial fibrillation]] more than [[digoxin]] did.<ref name="pmid12074271">{{cite journal |author=Atarashi H, Inoue H, Fukunami M, Sugi K, Hamada C, Origasa H |title=Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation |journal=Circ. J. |volume=66 |issue=6 |pages=553–6 |date=June 2002 |pmid=12074271 |doi= 10.1253/circj.66.553|url=http://joi.jlc.jst.go.jp/JST.JSTAGE/circj/66.553?from=PubMed |format={{dead link|date=May 2010}}}}</ref>


It has shown effectiveness when given orally.<ref name="pmid603737">{{cite journal |author=Reid PR, Greene HL, Varghese PJ |title=Suppression of refractory arrhythmias by aprindine in patients with the Wolff-Parkinson-White syndrome |journal=Br Heart J |volume=39 |issue=12 |pages=1353–60 |date=December 1977 |pmid=603737 |pmc=483421 |doi= 10.1136/hrt.39.12.1353|url=http://heart.bmj.com/cgi/pmidlookup?view=long&pmid=603737}}</ref>


 
==References==
 
{{reflist|2}}
==Overview==
'''Aprindine''' is a Class 1b [[antiarrhythmic agent]].


{{Antiarrhythmic agents}}
{{Antiarrhythmic agents}}


[[Category:Antiarrhythmic agents]]
[[Category:Antiarrhythmic agents]]
[[Category:Drugs]]
[[Category:Cardiovascular Drugs]]
{{WikiDoc Help Menu}}
[[Category:Drug]]
{{WikiDoc Sources}}

Latest revision as of 22:10, 23 July 2014

Aprindine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H30N2
Molar mass322.487 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Aprindine

Articles

Most recent articles on Aprindine

Most cited articles on Aprindine

Review articles on Aprindine

Articles on Aprindine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Aprindine

Images of Aprindine

Photos of Aprindine

Podcasts & MP3s on Aprindine

Videos on Aprindine

Evidence Based Medicine

Cochrane Collaboration on Aprindine

Bandolier on Aprindine

TRIP on Aprindine

Clinical Trials

Ongoing Trials on Aprindine at Clinical Trials.gov

Trial results on Aprindine

Clinical Trials on Aprindine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Aprindine

NICE Guidance on Aprindine

NHS PRODIGY Guidance

FDA on Aprindine

CDC on Aprindine

Books

Books on Aprindine

News

Aprindine in the news

Be alerted to news on Aprindine

News trends on Aprindine

Commentary

Blogs on Aprindine

Definitions

Definitions of Aprindine

Patient Resources / Community

Patient resources on Aprindine

Discussion groups on Aprindine

Patient Handouts on Aprindine

Directions to Hospitals Treating Aprindine

Risk calculators and risk factors for Aprindine

Healthcare Provider Resources

Symptoms of Aprindine

Causes & Risk Factors for Aprindine

Diagnostic studies for Aprindine

Treatment of Aprindine

Continuing Medical Education (CME)

CME Programs on Aprindine

International

Aprindine en Espanol

Aprindine en Francais

Business

Aprindine in the Marketplace

Patents on Aprindine

Experimental / Informatics

List of terms related to Aprindine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Aprindine is a Class 1b antiarrhythmic agent.[1]

In one study, it delayed atrial fibrillation more than digoxin did.[2]

It has shown effectiveness when given orally.[3]

References

  1. Sato R, Hisatome I, Tanaka Y; et al. (September 1991). "Aprindine blocks the sodium current in guinea-pig ventricular myocytes". Naunyn Schmiedebergs Arch. Pharmacol. 344 (3): 331–6. doi:10.1007/bf00183008. PMID 1660104.
  2. Atarashi H, Inoue H, Fukunami M, Sugi K, Hamada C, Origasa H (June 2002). "Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation" ([dead link]). Circ. J. 66 (6): 553–6. doi:10.1253/circj.66.553. PMID 12074271.
  3. Reid PR, Greene HL, Varghese PJ (December 1977). "Suppression of refractory arrhythmias by aprindine in patients with the Wolff-Parkinson-White syndrome". Br Heart J. 39 (12): 1353–60. doi:10.1136/hrt.39.12.1353. PMC 483421. PMID 603737.

Template:Antiarrhythmic agents